Transcription
Hello, my name is Dr. Jerome Canady. I'm CEO of US Medical Innovations. So cold atmospheric plasma is new technology that causes develops electromagnetic field. And this electromagnetic field develops what we call reactive oxygen or nitrogen species. These species disseminate through the cellular membrane of the human body, which a certain section of the cell cycle causes death to the cell. This type of cancer will affect all types of solid tumors, from ovarian cancer to colon cancer to lung cancer, breast cancer, and all the subtypes of breast cancers, especially for triple negative breast cancer, where to date, there's no treatment for these things, women who have triple negative breast cancer in our laboratory, we've been able to kill the the triple negative breast cancer 100%. What's amazing about this technology, there's no damage to the normal biological tissue. So if he hits a nerve, he hits the artery that hits the brain cell normal brain cells, it has no effect on the tissue. You can see this blue light, which is truly a lightsaber. We spray this around the tissue for five to seven minutes which will kill the microscopic tumor bed. We're the first in the world to bring this from out of the laboratory for the treatment of cancer. We just completed a phase one clinical trial. If we're able to resect the pain. If we're able to resect these tumors. I then use cold plasma. The trial basically as demonstrated 75 65% of those patients are still alive after three years, as well as the recurrence rate. There's been no recurrence, almost 85% of the patients had no recurrence. Within the three year period, we've been following these patients. The trial was conducted at Rush University in Chicago, Illinois, and Sheba Medical Center in Tel Hashomer Israel. I'm here to attend the meeting at LSI and to meet participate with the investors and innovators from around the world.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
